The FDA Modernization Act 1997 required a public database of certain drug trials. President Bill Clinton signed it into law on November 21, 1997. ClinicalTrials.gov, the website that grew from that requirement, opened in 2000.
November 21 marks the law's 29th anniversary. Its lasting contribution was a way for people to find studies and ask better questions about them. A trial listing was never a promise that a treatment worked.
FDA Modernization Act 1997: the November 21 document
The full name is the Food and Drug Administration Modernization Act of 1997, often shortened to FDAMA. The original law is headed “PUBLIC LAW 105–115—NOV. 21, 1997” and ends “Approved November 21, 1997.”
Those dates mark enactment, when the bill became law. They don't mark the website's launch or permission to market any particular medicine.
Section 113 amended the Public Health Service Act. It directed the health secretary, acting through the National Institutes of Health, to establish and operate a clinical-trial database. Congress supplied the instruction; building a public service came next.
The day before: studies existed, but finding them was harder
The law didn't invent clinical trials or the first trial information service. People already had studies to consider and other trial information services to search.
The problem was finding a useful starting point across those scattered sources. Patient groups wanted information they could understand, including where a study happened and whom to contact. The new database was meant to serve patients and families as well as researchers.
What section 113's trial registry required
The original requirement covered certain trials of experimental drugs for serious or life-threatening diseases, whether federally or privately funded. It called for understandable information about the treatment's purpose, who could join, study locations and a contact person.
It wasn't a requirement that every medical study publish a results table. The text allowed certain results information with the sponsor's consent. A sponsor is the person or organization responsible for a study.
That distinction still matters when reading about MOTS-c, a peptide, or short chain of protein building blocks. CB4211’s developer described it as an analog of MOTS-c, meaning a modified relative. A registry can identify which molecule was tested. It doesn't make the two interchangeable.
2000: the public website arrives
The National Library of Medicine, part of the National Institutes of Health, built ClinicalTrials.gov. Its official timeline gives the public launch date as February 29, 2000.
Alexa McCray and Nicholas Ide, two of its builders, described the project in the Journal of the American Medical Informatics Association in 2000. They put patients and other members of the public at the center of its design.
The difference is simple: 1997 supplied the legal requirement. In 2000, people could search the resulting website.
2007–2017: reporting results becomes a separate duty
Later changes made the database more than a place to find studies. The 2016 account by registry officials in the New England Journal of Medicine explains the expanded duties and the rule that clarified them.
| Year | What changed |
|---|---|
| 2007 | The FDA Amendments Act broadened registration requirements and required summary results for certain trials of drugs, biological products and devices. |
| 2008 | ClinicalTrials.gov launched its results database in September. |
| 2016 | A final rule, a completed government regulation, clarified which trials were covered and what information had to be submitted. |
| 2017 | That rule took effect on January 18; the compliance date was April 18. |
These were later additions, rather than requirements already fully present in 1997. Registration describes a study. Results reporting tells readers what happened to its participants. A journal paper is another way findings can become public.
2021: CB4211 shows why those distinctions matter
The CB4211 study record, NCT03998514, lists 88 participants, completion on April 19, 2021, and a last posted update of May 11, 2021. It describes early human testing focused on safety and how the body handles the drug.
As of November 20, 2026, the day this article was written, that record still has no posted results. CohBar released preliminary findings in August 2021, so an empty results tab doesn't mean nothing was ever announced.
“Completed” means the study ended. It doesn't mean the treatment worked or received marketing permission. And findings about CB4211 cannot establish a dose, side-effect rate or benefit for native MOTS-c, the original peptide sequence. The MOTS-c versus CB4211 guide explains that separate evidence question.
2026: a clearer view of changes to a study record
As of November 20, 2026, the day this article was written, ClinicalTrials.gov's October 28, 2026 release notes report improved comparisons between two record versions. Its September 15 update also made the selected comparison view persist between sessions. Record History lets readers examine changes to a study's information over time; a better display doesn't add treatment evidence.
The distinction between a study plan and a result remains useful. So does checking the last posted update rather than treating an old record as a fresh announcement.
What this means in a MOTS-c prescribing conversation
A trial number helps locate evidence. It doesn't replace reading which substance was studied, who received it and what was measured.
An IND, or Investigational New Drug application, is a filing that supports a defined human investigation. It isn't permission to market the drug. The phases of clinical trials describe stages of testing, rather than a guarantee that the next stage will succeed.
Section 127 of the 1997 law added section 503A to the Federal Food, Drug, and Cosmetic Act. It set conditions for pharmacy compounding. In 2002, the Supreme Court held that restrictions on advertising particular compounded drugs and soliciting prescriptions violated the First Amendment (535 U.S. 357). It did not decide whether the rest of section 503A could stand. The Ninth Circuit held that the whole section fell with those restrictions. The Fifth Circuit later held that the rest could stand. On November 27, 2013, the Drug Quality and Security Act (Public Law 113–54) removed the speech restrictions, clarifying that section 503A applies nationwide.
As of November 20, 2026, the day this article was written, FDA explains that it doesn't review compounded drugs for safety, effectiveness or quality before marketing.
MOTS-c prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
a licensed provider may still prescribe — that decision is between you and your doctor.
From a study record to an individual visit
A routine MOTS-c prescription doesn't enroll someone in the CB4211 trial or transfer that study's findings to their medication. The useful discussion concerns the actual preparation, the person's medical history and the limits of the matching evidence.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The database helps make the evidence visible. The provider still has to interpret it for the person in front of them.





